Balchem Résultats passés
Passé contrôle des critères 5/6
Balchem a connu une croissance annuelle moyenne de ses bénéfices de 11.2%, tandis que le secteur Chemicals a vu ses bénéfices augmenter de en baisse à 4% par an. Les revenus ont augmenté de en hausse à un taux moyen de 6% par an. Le rendement des capitaux propres de Balchem est 12.3% et ses marges nettes sont de 15%.
Informations clés
11.20%
Taux de croissance des bénéfices
11.08%
Taux de croissance du BPA
| Chemicals Croissance de l'industrie | 12.93% |
| Taux de croissance des recettes | 5.96% |
| Rendement des fonds propres | 12.30% |
| Marge nette | 14.95% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Seeking Alpha • Mar 27
Balchem: An Attractive Valuation Makes This Stock A Buy
Summary Balchem delivered strong Q4 results, with revenue up nearly 10% year-over-year and all segments posting growth. BCPC boasts a 17-year streak of double-digit dividend hikes, supported by a payout ratio consistently below 20%. The stock trades at a roughly 25% discount to its estimated fair value, with robust forward return potential exceeding 14%. I rate BCPC a 'Buy', citing resilient segment demand, disciplined capital allocation, and attractive free cash flow valuation despite raw material and tariff risks. Read the full article on Seeking Alpha
Nouveau récit • Mar 13
Long-Term Nutrition And Health Trends Will Support Stronger Margins And Earnings Potential
Catalysts About Balchem Balchem supplies specialty nutrients and ingredients for human, animal and plant health, along with performance gases and related solutions. What are the underlying business or industry changes driving this perspective?
Nouveau récit • Feb 26
Encapsulation Investments And International Expansion Will Shape Balanced Future For Nutrition Specialist
Catalysts About Balchem Balchem produces specialty nutrition and ingredient solutions for human, animal and plant health, along with performance gases. What are the underlying business or industry changes driving this perspective?
Mise à jour du récit • Feb 17
BCPC: Dividend Increase And Buyback Program Will Support Steady Future Returns
Analysts kept their Balchem fair value estimate broadly steady at $191, pointing to only very small tweaks in assumptions such as discount rate, long term revenue growth, profit margin and future P/E as the basis for maintaining their target level. What's in the News On December 9, 2025, Balchem Corporation's Board of Directors declared an annual dividend of $0.96 per share, payable on January 20, 2026, to stockholders of record as of December 23, 2025.Article d’analyse • Feb 15
If EPS Growth Is Important To You, Balchem (NASDAQ:BCPC) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Mise à jour du récit • Feb 03
BCPC: Share Repurchases And Higher Dividend Will Support Attractive Future Returns
Analysts have maintained their fair value estimate for Balchem at US$191. They have made only minimal adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions, indicating that their overall view on the stock's valuation drivers remains essentially unchanged.Article d’analyse • Feb 01
Is Now An Opportune Moment To Examine Balchem Corporation (NASDAQ:BCPC)?
Balchem Corporation ( NASDAQ:BCPC ), is not the largest company out there, but it saw a decent share price growth of...Mise à jour du récit • Jan 20
BCPC: Share Repurchases And Rising Dividend Will Support Attractive Future Returns
Analysts have maintained their Balchem fair value estimate at US$191, with only small tweaks to the discount rate, revenue growth, profit margin, and forward P/E assumptions. This reflects a largely unchanged view on the stock's risk and earnings profile.Mise à jour du récit • Jan 05
BCPC: Share Repurchases And Dividend Increases Will Support Attractive Future Returns
Analysts kept their fair value estimate for Balchem steady at US$191, pointing to only very small model tweaks in the discount rate, revenue growth, margin and forward P/E assumptions rather than any change in their overall view of the company. What's in the News Balchem Corporation announced a share repurchase program authorizing the company to buy back up to 4,000,000 shares, with no expiration date on the program (Key Developments).Mise à jour du récit • Dec 20
BCPC: Share Repurchases And Dividend Increases Will Drive Attractive Future Returns
Analysts have maintained their price target on Balchem at approximately $191.00. This reflects only marginal tweaks to underlying assumptions such as discount rate, revenue growth, and profit margin, rather than a material change in their outlook.Mise à jour du récit • Dec 06
BCPC: Share Repurchases Will Support Attractive Long Term Return Potential
Analysts have lowered their price target on Balchem by approximately $9 to about $191 per share, reflecting more cautious assumptions around revenue growth and profit margins, even though long term valuation multiples are slightly higher. What's in the News Completed a long running share repurchase program, buying back a total of 3,475,622 shares, or about 12.76% of shares outstanding, for approximately $190.58 million since the authorization began in 1999 (Key Developments) During the most recent quarter from July 1, 2025 to September 30, 2025, repurchased 95,760 shares, roughly 0.3% of shares outstanding, for $15.42 million as the final tranche under the existing buyback plan (Key Developments) Valuation Changes The Fair Value Estimate has fallen modestly from about $200.33 to $191.00 per share, reflecting a slightly more conservative outlook.Article d’analyse • Dec 01
Balchem (NASDAQ:BCPC) Is Experiencing Growth In Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Article d’analyse • Oct 10
Some Shareholders Feeling Restless Over Balchem Corporation's (NASDAQ:BCPC) P/E Ratio
Balchem Corporation's ( NASDAQ:BCPC ) price-to-earnings (or "P/E") ratio of 31.9x might make it look like a strong sell...Article d’analyse • Sep 26
Balchem (NASDAQ:BCPC) Could Easily Take On More Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Aug 26
Estimating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Balchem fair value estimate is US$174 With US$162 share price...Article d’analyse • Jul 21
Balchem (NASDAQ:BCPC) Is Looking To Continue Growing Its Returns On Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Article d’analyse • Jun 23
These 4 Measures Indicate That Balchem (NASDAQ:BCPC) Is Using Debt Safely
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Oct 28
Balchem's Q3 Shows Record Earnings And Valuation Pressure
Summary Balchem Corporation shows strong long-term growth potential in high-margin segments and product innovation, but faces challenges in Animal Nutrition & Health and rising costs. Balchem's financial momentum in Q3 2024 includes record earnings, improved margins, and significant debt reduction, despite missing revenue estimates. BCPC stock's high P/E ratio of 39.82x suggests big market expectations, but the current valuation may be too high given existing challenges. I rate Balchem as a “Hold” due to high valuation, operational challenges, and potential seasonal slowdown, advising cautious investors to wait for a better entry point. Read the full article on Seeking Alpha
Nouveau récit • Aug 29
Innovating In Nutrition And Health Sectors Drives Strong Financial Growth And Market Expansion
Launch of Optifolin+ in the nutrition segment and strong Human Nutrition & Health sales indicate potential for market share expansion and sustained revenue growth.Seeking Alpha • May 10
Balchem: A Tale Of Two Businesses
Summary Balchem Corporation's Q1 2024 earnings surpassed expectations, but the company's full-year bottom-line expansion could be slower than what it achieved for the first quarter. The Human Nutrition & Health segment is riding on the supplements market's growth, while the Animal Nutrition & Health segment is encountering stiff competition in the European animal feed market. It is a tale of two businesses for BCPC, which implies that the stock warrants a Neutral or Hold rating. Read the full article on Seeking AlphaSeeking Alpha • Feb 21
Balchem: Potential Turnaround Is In The Price
Summary Balchem registered a -2.5% top-line miss for the fourth quarter of 2023, which is attributable to the underperformance of its Animal Nutrition business. BCPC is well-positioned to achieve positive top line and earnings expansion in the current year, but I deem the stock's valuations to be fair. The Company continues to be rated as a Hold, as my opinion is that the expected 2024 turnaround for BCPC is priced in. Read the full article on Seeking AlphaVentilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Balchem gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 1,057 | 158 | 149 | 20 |
| 31 Dec 25 | 1,037 | 155 | 143 | 19 |
| 30 Sep 25 | 1,014 | 149 | 140 | 18 |
| 30 Jun 25 | 986 | 143 | 136 | 18 |
| 31 Mar 25 | 965 | 137 | 133 | 17 |
| 31 Dec 24 | 954 | 128 | 136 | 17 |
| 30 Sep 24 | 942 | 122 | 144 | 16 |
| 30 Jun 24 | 932 | 117 | 139 | 16 |
| 31 Mar 24 | 930 | 115 | 131 | 16 |
| 31 Dec 23 | 922 | 109 | 120 | 15 |
| 30 Sep 23 | 926 | 103 | 117 | 14 |
| 30 Jun 23 | 941 | 99 | 122 | 13 |
| 31 Mar 23 | 946 | 99 | 126 | 12 |
| 31 Dec 22 | 942 | 105 | 121 | 12 |
| 30 Sep 22 | 923 | 109 | 116 | 14 |
| 30 Jun 22 | 877 | 109 | 109 | 14 |
| 31 Mar 22 | 842 | 102 | 107 | 14 |
| 31 Dec 21 | 799 | 96 | 102 | 14 |
| 30 Sep 21 | 767 | 93 | 100 | 11 |
| 30 Jun 21 | 744 | 90 | 100 | 11 |
| 31 Mar 21 | 715 | 88 | 99 | 10 |
| 31 Dec 20 | 704 | 85 | 102 | 10 |
| 30 Sep 20 | 689 | 83 | 104 | 11 |
| 30 Jun 20 | 673 | 82 | 104 | 11 |
| 31 Mar 20 | 661 | 81 | 102 | 11 |
| 31 Dec 19 | 644 | 80 | 95 | 11 |
| 30 Sep 19 | 641 | 80 | 89 | 12 |
| 30 Jun 19 | 637 | 78 | 84 | 12 |
| 31 Mar 19 | 639 | 78 | 82 | 12 |
| 31 Dec 18 | 644 | 79 | 84 | 12 |
| 30 Sep 18 | 639 | 100 | 83 | 11 |
| 30 Jun 18 | 635 | 97 | 84 | 11 |
| 31 Mar 18 | 618 | 94 | 81 | 10 |
| 31 Dec 17 | 595 | 90 | 81 | 9 |
| 30 Sep 17 | 576 | 64 | 82 | 9 |
| 30 Jun 17 | 564 | 62 | 82 | 8 |
| 31 Mar 17 | 556 | 60 | 82 | 7 |
| 31 Dec 16 | 553 | 56 | 83 | 7 |
| 30 Sep 16 | 545 | 56 | 77 | 7 |
| 30 Jun 16 | 547 | 56 | 76 | 7 |
| 31 Mar 16 | 543 | 56 | 72 | 6 |
| 31 Dec 15 | 552 | 60 | 68 | 6 |
| 30 Sep 15 | 582 | 63 | 71 | 6 |
| 30 Jun 15 | 603 | 64 | 70 | 6 |
Des revenus de qualité: BCPC a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de BCPC sont plus élevées que l'année dernière BCPC. (15%) sont plus élevées que l'année dernière (14.2%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de BCPC ont augmenté de 11.2% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de BCPC au cours de l'année écoulée ( 15.8% ) dépasse sa moyenne sur 5 ans ( 11.2% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices BCPC au cours de l'année écoulée ( 15.8% ) a dépassé celle du secteur Chemicals 0.1%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de BCPC ( 12.3% ) est considéré comme faible.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/20 00:43 |
| Cours de l'action en fin de journée | 2026/06/18 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Balchem Corporation est couverte par 9 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Robert Labick | CJS Securities, Inc. |
| Timothy Ramey | D.A. Davidson & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |